We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Low-Dose IL-2 Therapy in Autoimmune and Rheumatic Diseases.
- Authors
Graßhoff, Hanna; Comdühr, Sara; Monne, Luisa R.; Müller, Antje; Lamprecht, Peter; Riemekasten, Gabriela; Humrich, Jens Y.
- Abstract
Regulatory T cells (Treg) are crucial for the maintenance of peripheral tolerance and for the control of ongoing inflammation and autoimmunity. The cytokine interleukin-2 (IL-2) is essentially required for the growth and survival of Treg in the peripheral lymphatic tissues and thus plays a vital role in the biology of Treg. Most autoimmune and rheumatic diseases exhibit disturbances in Treg biology either at a numerical or functional level resulting in an imbalance between protective and pathogenic immune cells. In addition, in some autoimmune diseases, a relative deficiency of IL-2 develops during disease pathogenesis leading to a disturbance of Treg homeostasis, which further amplifies the vicious cycle of tolerance breach and chronic inflammation. Low-dose IL-2 therapy aims either to compensate for this IL-2 deficiency to restore a physiological state or to strengthen the Treg population in order to be more effective in counter-regulating inflammation while avoiding global immunosuppression. Here we highlight key findings and summarize recent advances in the clinical translation of low-dose IL-2 therapy for the treatment of autoimmune and rheumatic diseases.
- Subjects
RHEUMATISM; SUPPRESSOR cells; LYMPHOID tissue; CYTOKINES; IMMUNOLOGICAL tolerance
- Publication
Frontiers in Immunology, 2021, Vol 11, pN.PAG
- ISSN
1664-3224
- Publication type
Article
- DOI
10.3389/fimmu.2021.648408